Evidence map›Paper›PMID 32682839›Full record

ArticleOphthalmology2021

On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics.

Anand D Gopal, Joshua D Wallach, Saloni A Shah, Carl Regillo, Joseph S Ross

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. COVID-19 impact on research and publication ethics.Medical hypothesis, discovery & innovation ophthalmology journal · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anand D GopalWills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: ananddgopal@gmail.com.
Joshua D WallachDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.
Saloni A ShahSidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.
Carl RegilloRetina Service, Wills Eye Hospital, Philadelphia, Pennsylvania.
Joseph S RossDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.

Funding

Understanding hospital value: provider, hospital and community effectsR01HS022882 · AHRQ · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HORWITZ, LEORA · 2014 to 2023
$2.9M
Leveraging Physician Networks to Improve Care and Outcomes for Low-Income PopulationsR01HL144644 · NHLBI · YALE UNIVERSITY · PI NDUMELE, CHIMA · 2019 to 2021
$1.6M
Medical reversals: De-implementing ineffective and unsafe treatmentsR01HS025164 · AHRQ · UNIVERSITY OF MINNESOTA · PI KARACA-MANDIC, PINAR · 2017 to 2020
$1.4M
Impact of Publicity Reporting Hospital Outcome Measures for Older AdultsK08AG032886 · NIA · YALE UNIVERSITY · PI ROSS, JOSEPH SOLOMON · 2008 to 2012
$738k
AHRQ HHS R01 HS022882AHRQ HHS R01 HS025164FDA HHS U01 FD004585FDA HHS U01 FD005938NHLBI NIH HHS R01 HL144644NIA NIH HHS K08 AG032886
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug ApprovalOff-Label UseDelivery of Health CareEye DiseasesHumansOphthalmic SolutionsPharmaceutical PreparationsPrescription DrugsProduct LabelingUnited StatesUnited States Food and Drug AdministrationOphthalmic SolutionsPharmaceutical PreparationsPrescription Drugs

Identifiers

PMID32682839
PMCPMC9900733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.